Financial Data and Key Metrics Changes - Total revenue for 2024 was $518.8 million, a slight increase of 0.5% compared to $516.4 million in 2023, with ODR revenue growing by 31.9% and GCR revenue declining by 31.9% [28] - Total gross profit for the year increased by 20.9% from $119.3 million to $144.3 million, with total gross margin rising to 27.8% from 23.1% in 2023 [31] - Adjusted EBITDA for 2024 was $63.7 million, up 36.1% from $46.8 million in 2023, exceeding the guidance of $60 million to $63 million [37] - Net income grew by 48.8% to $30.9 million, with earnings per diluted share increasing by 46% from $1.76 to $2.57 [38] Business Line Data and Key Metrics Changes - ODR revenue accounted for 66.6% of total revenue for the year, up from 50.7% in 2023, while GCR revenue accounted for the remainder [28] - ODR gross profit contributed $107.8 million or 74.7% of total gross profit dollars, with ODR gross margins expanding to 31.2% from 29% in 2023 [31] - GCR gross profit declined by $6.7 million or 15.5%, but GCR gross margins improved to 21.1% from 17% in 2023 due to selectivity in higher quality projects [32] Market Data and Key Metrics Changes - The company is focusing on six mission-critical market verticals, with healthcare emerging as the largest, contributing significantly to operational continuity in medical facilities [4][5] - The industrial manufacturing sector has become the second largest vertical, with strategic acquisitions enhancing capabilities and partnerships with facility owners [19] Company Strategy and Development Direction - The company is shifting its revenue mix towards the ODR segment, targeting an eventual 80% of total revenue from ODR and 20% from GCR [22] - The M&A strategy is crucial for growth, with a target of acquiring $8 million to $10 million in adjusted EBITDA per year [21] - The company aims to expand its geographic footprint through acquisitions while enhancing service offerings to drive margin expansion [20] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving organic top-line revenue growth of 10% to 15% in 2025, driven by the shift towards ODR revenue and the impact of acquisitions [23] - The company anticipates total revenue in the range of $610 million to $630 million for 2025, with a focus on improving gross margins [24] - Management highlighted the importance of building long-term relationships with customers to capture recurring revenue opportunities [14] Other Important Information - SG&A expenses for the year were $97.2 million, up from $87.4 million in 2023, with a target to reduce this as a percentage of revenue in 2025 [34][35] - Operating cash flow for the fourth quarter was $19.3 million, a 38.7% increase from 2023, while free cash flow for the year was $52.3 million, an increase of 42.6% [39] Q&A Session Summary Question: What is the expected organic growth for 2025? - Management indicated that the organic growth target of 10% to 15% refers to the overall business, not just ODR [44][45] Question: What is the implied organic growth in ODR? - Management suggested that ODR organic growth could range from 23% to 46% based on adjusted EBITDA and revenue perspectives [50][51] Question: How does the company plan to achieve OEM-level gross margins? - Management noted that achieving OEM-level margins is a long-term goal, requiring a shift towards ODR revenue and the development of an integrated platform across locations [52][54] Question: How is the company progressing in developing trusted adviser relationships with existing customers? - Management acknowledged that building these relationships takes time, emphasizing the importance of proactive engagement and capital planning [61][62] Question: What is the company's strategy for expanding its MSA count? - Management indicated that while there are opportunities for organic growth, the majority of expansion will come from acquisitions [94][95]
Limbach(LMB) - 2024 Q4 - Earnings Call Transcript